The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment

Схожие документы

• Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment
  по: Dowell, J, et al.
  Опубликовано: (2008)
• Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
  по: Schnell, David, et al.
  Опубликовано: (2014)
• Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
  по: Desai, Amit, et al.
  Опубликовано: (2016)
• Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
  по: Tortorici, Michael A., et al.
  Опубликовано: (2010)
• Dalbavancin safety in the phase 2/3 clinical development program
  по: Seltzer, E, et al.
  Опубликовано: (2008)